New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
08:24 EDTTKMRTekmira Ebola drug could see emergency use in U.S., says Maxim
Maxim said the FDA's decision to change its full clinical hold on TKM-Ebola to a partial hold paves the way for potential emergency use of the drug in the U.S., if needed. Maxim noted that Tekmira's DOD contract for development of the treatment is initially worth $140M, adding that the firm expect Tekmira to receive a government supplier contract by 2018 for the drug. Maxim keeps its Buy rating and $23 price target on the stock.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
18:05 EDTTKMRNYC boy with Ebola-like symptoms tests negative for disease, WSJ says
Subscribe for More Information
11:24 EDTTKMRNovavax rises after announcing Ebola vaccine development program
Subscribe for More Information
07:27 EDTTKMRYoung NYC boy tested for Ebola, NY Post reports
Subscribe for More Information
October 26, 2014
14:40 EDTTKMRFDA issues Emergency Use Authorization for Ebola diagnostic tests
Subscribe for More Information
October 24, 2014
10:55 EDTTKMRDallas nurse now Ebola virus free, to be released, NBC reports
NBC and other media outlets cites NIH on Nina Pham's release. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED). Reference Link
October 23, 2014
15:25 EDTTKMRNew York confirms health care worker being tested for Ebola
Subscribe for More Information
14:58 EDTTKMRNew York doctor rushed to hospital with Ebola-like symptoms, NY Post reports
Subscribe for More Information
06:22 EDTTKMREU to boost Ebola research with EUR 24.4M
The European Commission has today announced EUR 24.4M from the EU budget for urgently needed Ebola research. The funding will go to five projects, ranging from a large-scale clinical trial of a potential vaccine, to testing existing and novel compounds to treat Ebola. The money from Horizon 2020, the EU research and innovation program, will be provided via a fast-track procedure in order to start work as soon as possible. The Commission is also working with industry on the further development of vaccines, drugs and diagnostics for Ebola and other haemorrhagic diseases within the Innovative Medicines Initiative. The funding will be provided following proposals from teams across the EU and in numerous 3rd countries, which were evaluated by an independent group of experts. The Commission has also asked the European and Developing Countries Clinical Trials Partnership to include emerging epidemics of concern to Africa, including Ebola, in its work plan. This will allow to fund clinical trials on drugs, vaccines and diagnostics in upcoming calls. Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
October 22, 2014
06:41 EDTTKMRWHO fast-tracking testing of two Ebola vaccines, Guardian reports
Subscribe for More Information
October 21, 2014
19:53 EDTTKMRTekmira commences limited GMP manufacture of Ebola drug
Tekmira Pharmaceuticals provided an update on its Ebola program. The company is reporting it has commenced limited GMP manufacture of a new therapeutic specifically targeting the Ebola, Guinea variant, which is the viral variant responsible for the Ebola epidemic currently prevalent in West Africa. Supply of this new product will be available in early December, for potential use by various collaborators. The Company has completed the design of a modified RNAi therapeutic specifically targeting the Ebola viral variant, now termed 'Ebola-Guinea.' The company's IND for TKM-Ebola remains on partial clinical hold with respect to the multiple ascending dosing in healthy subjects. The company expects this matter to be resolved this quarter.
09:48 EDTTKMRShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information
07:21 EDTTKMRiBio valuation will be hard to maintain, TheStreet's Feuerstein says
iBio's current valuation will be hard to maintain "even under the best Ebola stockpiling scenario," TheStreet's Adam Feuerstein argues. He notes Ebola related stocks fell yesterday after the quarantines related to Thomas Duncan ended. Reference Link
October 20, 2014
09:09 EDTTKMREMA encourages applications for orphan designation for Ebola treatments
The European Medicines Agency encourages developers of treatments or vaccines against Ebola to apply for orphan designation. Applications for orphan designation of Ebola medicines will be treated as a priority and EMA has committed to fast-tracking their evaluation, the regulator announced. Drug companies that are working on experimental Ebola vaccines and treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX), NewLink Genetics (NLNK) and GlaxoSmithKline (GSK).
October 19, 2014
16:44 EDTTKMREbola drug discovery efforts intensify, WSJ says
Subscribe for More Information
13:39 EDTTKMRCarnival cruise passenger tests negative for Ebola, Reuters says
Subscribe for More Information
October 17, 2014
14:50 EDTTKMRBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTTKMRSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use